Clinical Trial

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-15
Trial Details
NCT Number NCT04774718
Lead Sponsor Hoffmann-La Roche
Conditions ALK Fusion-positive Solid or CNS Tumors
Enrollment 42 participants
Start Date 2021-09-14
Primary Completion 2032-02-28 (estimated)
Study Completion 2032-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-14